inactivated varicella vaccine
Vaccineexperimental
Clinical trial activity
23 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
16
Phase 3
13
Phase 4
5
Earliest trial started Sep 1, 2003 (NCT00792623)
Timeline
Indications
Approved for
Studied for
- Chickenpox · Phase 4
- COVID-19 · Phase 4
- Dengue · Phase 1/Phase 2
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 4
- Esophageal and Gastric Varices · Phase 4
- Healthy Volunteers · Phase 3
- Hepatitis A · Phase 4
- Herpes Zoster Vaccine · Phase 3
- Influenza Vaccines · Phase 4
- Measles · Phase 4
- Measles-Mumps-Rubella Vaccine · Phase 4
- Meningococcal Infections · Phase 3
- Mumps · Phase 4
- Respiratory Syncytial Virus Vaccines · Phase 3
- Rubella · Phase 4
Mechanism of action
- Human herpesvirus 3Immunity, active
Human herpesvirus 3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- inactivated varicella vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06891872 | Phase 4 | May 31, 2025 | Sinovac Biotech Co., Ltd |
| NCT06855160 | Phase 3 | Apr 17, 2025 | GlaxoSmithKline |
| NCT06806137 | Phase 3 | Mar 5, 2025 | GlaxoSmithKline |
| NCT06740630 | Phase 3 | Dec 17, 2024 | GlaxoSmithKline |
| NCT06693895 | Phase 3 | Nov 19, 2024 | GlaxoSmithKline |
| NCT06987942 | Phase 4 | Sep 21, 2024 | Sinovac Biotech Co., Ltd |
| NCT06994052 | Phase 4 | Sep 21, 2024 | Sinovac Biotech Co., Ltd |
| NCT06397768 | Phase 3 | May 13, 2024 | Sanofi-Aventis |
| NCT06314724 | Phase 3 | Mar 1, 2024 | Sinovac Biotech Co., Ltd |
| NCT05952505 | Phase 4 | Aug 31, 2023 | China National Biotec Group Co., Ltd, Government of China |
| NCT05794230 | Phase 3 | Mar 27, 2023 | Sanofi-Aventis |
| NCT06313762 | N/A | Jan 18, 2022 | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
| NCT05084508 | Phase 2 | Jan 4, 2022 | GlaxoSmithKline, IQVIA |
| NCT03673462 | Phase 3 | Sep 17, 2018 | Sanofi-Aventis |
| NCT03537508 | Phase 3 | Apr 25, 2018 | Sanofi-Aventis |
| NCT03330171 | Phase 4 | Apr 10, 2017 | University of the Witwatersrand |
| NCT03375502 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2016 | Green Cross Corporation |
| NCT00969436 | Phase 3 | Nov 1, 2009 | GlaxoSmithKline |
| NCT00751348 | Phase 3 | Oct 1, 2008 | GlaxoSmithKline |
| NCT00568334 | Phase 2 | Nov 1, 2007 | GlaxoSmithKline |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 11 | 10 | 2 | 2003 |
| Sanofi-Aventis | For profit | 4 | 4 | 1 | 2018 |
| Sinovac Biotech Co., Ltd | For profit | 4 | 4 | 2 | 2024 |
| China National Biotec Group Co., Ltd | For profit | 1 | 0 | 1 | 2023 |
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Government of China | Government | 1 | 1 | 1 | 2023 |
| Government of Thailand | Government | 1 | 0 | 1 | 2004 |
| Green Cross Corporation | For profit | 1 | 1 | 1 | 2016 |
| IQVIA | For profit | 1 | 0 | 1 | 2022 |
| United States Army | Government | 1 | 1 | 1 | 2004 |
| University of the Witwatersrand | Academic/Hospital | 1 | 1 | 1 | 2017 |
11 organizations
Page 1 / 1